|1.||Xu, Ze-Qi: 2 articles (04/2012 - 11/2011)|
|2.||Hammerschlag, Margaret R: 2 articles (03/2008 - 04/2003)|
|3.||Nicolau, David P: 2 articles (12/2003 - 10/2002)|
|4.||Nightingale, Charles H: 2 articles (12/2003 - 10/2002)|
|5.||Warren, Y: 2 articles (08/2001 - 09/2000)|
|6.||Tyrrell, K: 2 articles (08/2001 - 09/2000)|
|7.||Citron, D M: 2 articles (08/2001 - 09/2000)|
|8.||Goldstein, E J: 2 articles (08/2001 - 09/2000)|
|9.||Merriam, C V: 2 articles (08/2001 - 09/2000)|
|10.||Mott, Bryan T: 1 article (01/2015)|
09/01/2002 - "ABT-773 is a new 3-keto macrolide antibiotic that has been shown to be very effective against infections by Gram-positive microorganisms. "
09/01/2001 - "ABT-773 was also effective against Haemophilus influenzae lung infections in rats. "
09/01/2001 - "In acute systemic infections in mice, ABT-773 showed efficacy against macrolide-susceptible strains of Staphylococcus aureus, Streptococcus pneumoniae, S. "
01/01/2003 - "hominis and Ureaplasma spp. ABT-773 has great potential for further study for the treatment of infections due to mycoplasmas and ureaplasmas."
09/01/2004 - "We concluded that the C(max)/MIC(90) ratios, AUC/MIC(90) ratios, %T > MIC(90) values, and extended plasma and intrapulmonary half-lives provide a pharmacokinetic rationale for once-daily administration and are favorable for the treatment of cethromycin-susceptible pulmonary infections."
04/01/2003 - "Nasopharyngeal specimens for culture of Chlamydia pneumoniae were obtained from patients with community-acquired pneumonia enrolled in a randomized study comparing the novel ketolide antibiotic ABT-773 at a dose of 150 mg once a day to 150 mg twice a day, by mouth for 10 days. "
03/01/2013 - "Cethromycin appears to be a promising ketolide for the treatment of mild to moderate community-acquired pneumonia. "
03/01/2010 - "A new drug application for cethromycin was submitted to the United States Food and Drug Administration in 2008 for the treatment of community-acquired pneumonia. "
10/01/2002 - "pneumoniae in a murine pneumonia model and to describe the pharmacodynamic (PD) profile of cethromycin. "
03/01/2010 - "If cethromycin proves to be safe with regard to hepatotoxicity, it has great promise as an alternative to current standard therapy for community-acquired respiratory infections, especially pneumonia. "
|3.||Body Weight (Weight, Body)
10/01/2000 - "In the in vivo study mice were treated with ABT-773 (50, 100, and 200 mg/kg of body weight) or CLA (200 mg/kg). "
11/01/2011 - "pestis CO92 strain, 70 mg of cethromycin per kg of body weight (orally administered twice daily 24 h postinfection for a period of 7 days) provided complete protection to animals against mortality without any toxic effects. "
08/01/2004 - "Groups of mice were treated subcutaneously with cethromycin at 25 mg/kg of body weight or with placebo daily until sacrifice. "
10/01/2002 - "pneumoniae suspension containing 10(7) to 10(8) CFU/ml. Oral cethromycin was initiated 12 to 14 h postinoculation over a dosage range of 0.1 to 800 mg/kg of body weight/day. "
10/01/2001 - "When ABT-773 was given to infected guinea pigs by the intraperitoneal route (10 mg/kg of body weight), mean peak levels in plasma were 0.49 microg/ml at 0.5 h and 0.30 microg/ml at 1 h postinjection. "
|4.||Plague (Bubonic Plague)
11/01/2011 - "These data demonstrate that cethromycin is a potent antiplague drug that can be used to treat pneumonic plague."
11/01/2011 - "Further, no detectable plague bacilli were cultured from infected animals' blood and spleens following cethromycin treatment. "
03/01/2013 - "Cethromycin has an orphan drug designation for tularemia, plague, and anthrax prophylaxis. "
11/01/2011 - "Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin."
|7.||Bacterial Proteins (Bacterial Protein)
|9.||Anti-Bacterial Agents (Antibiotics)